Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: A case report

Cortés‑Mateus,Karen  S.; Holub,Katarzyna; Racca,Fabricio; Grau,Juan  José; Capdevila,Jaume

doi:10.3892/ol.2018.9069

Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: A case report

Authors:
- Karen S. Cortés‑Mateus
- Katarzyna Holub
- Fabricio Racca
- Juan José Grau
- Jaume Capdevila
View Affiliations

Affiliations: Medical Oncology Department and Radiation Oncology Department, University of Barcelona, IDIBAPS, Hospital Clinic Barcelona, 08036 Barcelona, Spain, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
Published online on: July 4, 2018 https://doi.org/10.3892/ol.2018.9069
Pages: 4085-4089

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Administration of external beam radiotherapy (EBRT) for a bulky recurrence or primary bulky tumor of differentiated thyroid carcinoma (DTC) is rare. No previous experience is available on the feasibility of administering EBRT simultaneously with systemic treatment with doxorubicin or sorafenib, or both. The present case study reported the results from two different institutions on 5 consecutive patients. Side effects and tolerance to radiotherapy plus systemic treatment with doxorubicin (20 mg/m2 intravenously weekly for 6/8 consecutive weeks) or sorafenib (400 mg/12 h orally for 8 weeks) or both, were analyzed in patients with DTC. The local response to radiotherapy and patient outcome was also analyzed. A total of 4 males and 1 female, aged 37‑62 years with cervical bulky mass DTC were included. The pathological tumor types were papillary (2 patients), follicular (2 patients) and medullar thyroid carcinoma (1 patient). The radiated cervical mass was local recurrence in 3 cases and primary tumor in the other two. The total dose of radiotherapy ranged between 50 and 64.8 Gy. Three patients received sorafenib, 1 patient received doxorubicin and 1 patient received both treatments. The total planned dose of radiotherapy was administered to all patients. Grade 2 anemia and erythrodysesthesia was the most frequent toxicity. Only the patient who received doxorubicin plus sorafenib had grade 3 toxicity consisting of lymphopenia, folliculitis and mucositis. All but 1 patient had a good local response to radiotherapy. The administration of EBRT concurrently with sorafenib and doxorubicin to patients with DTC with a bulky cervical mass is feasible.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al: SEER Cancer Statistics Review, 1975–2013. National Cancer Institute; Bethesda, MD: https://seer.cancer.gov/csr/1975_2013/September 12–2016
2	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
3	Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI and Garden AS: Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 74:1083–1091. 2009. View Article : Google Scholar : PubMed/NCBI
4	Terezakis SA, Lee KS, Ghossein RA, Rivera M, Tuttle RM, Wolden SL, Zelefsky MJ, Wong RJ, Patel SG, Pfister DG, et al: Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering cancer center experience. Int J Radiat Oncol Biol Phys. 73:795–801. 2009. View Article : Google Scholar : PubMed/NCBI
5	Gottlieb JA and Hill CS Jr: Chemotherapy of thyroid cancer with adriamycin: Experience with 30 patients. N Engl J Med. 290:193–197. 1974. View Article : Google Scholar : PubMed/NCBI
6	Kim JH and Leeper RD: Combination adriamycin and radiation therapy for locally advanced carcinoma of the thyroid gland. Int J Radiat Oncol Biol Phys. 9:565–567. 1983. View Article : Google Scholar : PubMed/NCBI
7	Kim JH and Leeper RD: Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 60:2372–2375. 1987. View Article : Google Scholar : PubMed/NCBI
8	Rosenthal CJ and Rotman M: Pilot study of interaction of radiation therapy with doxorubicin by continuous infusion. NCI Monogr. 285–290. 1988.PubMed/NCBI
9	Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, et al: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 31:895–902. 2013. View Article : Google Scholar : PubMed/NCBI
10	Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L and Myers JN: Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 17:1815–1827. 2011. View Article : Google Scholar : PubMed/NCBI
11	Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, et al: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014. View Article : Google Scholar : PubMed/NCBI
12	Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J, Vaz MÁ, Corral J, Obiols G, Grande E, Grau JJ and Tabernero J: Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 19:209–216. 2012. View Article : Google Scholar : PubMed/NCBI
13	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
14	Pacini F, Castagna MG, Brilli L and Pentheroudakis G: ESMO Guidelines Working Group: Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl 7:vii110–vii119. 2012. View Article : Google Scholar : PubMed/NCBI
15	Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, Shaha AR, Rivera M, Lin O, Wolden S, Lee NY and Pfister DG: Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiother Oncol. 101:425–430. 2011. View Article : Google Scholar : PubMed/NCBI
16	Brierley J and Sherman E: The role of external beam radiation and targeted therapy in thyroid cancer. Semin Radiat Oncol. 22:254–262. 2012. View Article : Google Scholar : PubMed/NCBI
17	Lee CG, Heijn M, de Tomasso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD and Boucher Y: Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565–5570. 2000.PubMed/NCBI
18	Murray L, Longo J, Wan J, Chung C, Wang L, Dawson L, Milosevic M, Oza A and Brade A: Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study. Radiather Oncol. 124:74–79. 2017. View Article : Google Scholar